Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Clinical Trials By clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
he Johnson & Johnson Office of the Chief Medical Officer (OCMO) is a global, functionally independent group responsible for leading safety and championing bioethical principles across Johnson & Johnson’s Pharmaceutical, Medical Device and Consumer Health sectors. Johnson & Johnson’s OCMO is constantly reviewing, monitoring and making decisions regarding the safety of our products through people-driven processes, initiatives and policies that are reinforced by a single medical safety standard, to which all our products are held.
Our Ethics- and Science-Driven Healthcare Initiatives
Within Johnson & Johnson’s Office of the Chief Medical Officer, safety assessment that is objective and science- and evidence-based is at the core of what we do and is built into every stage of our products’ life cycles—from development to post-launch. But just how do we do it?
The Johnson & Johnson Office of the Chief Medical Officer (OCMO) believes in the collective power of real-world observational data to complement clinical trial findings, and in sharing our insights widely to accelerate important research and policy developments and improve health outcomes for people everywhere.
Sharing of clinical trial data is critical to the advancement of the science that is the foundation of medicine and public health. It furthers our understanding of diseases, expands the base of knowledge needed to develop new treatments and generates new insights and more complete evidence to enable better healthcare decisions for patients.
Bioethics is an applied discipline that takes the principles of ethics and applies them to biological research, science and medicine. Adherence to bioethical principles, including transparency, integrity and respect for the rights and welfare of all persons, stems from Our Credo values and the commitment we make to our patients and consumers.
Our commitment to the safety and well-being of children has been a cornerstone of Johnson & Johnson's work for over 130 years, and we are committed to continue improving medical innovation for children.
Every day, we work to put people first—from proactive and transparent medical safety surveillance, to groundbreaking real-world evidence applications, pediatric clinical research advancements, early access innovation and more.
For Baby Safety Month, we sat down with the company's Head of Pediatric Drug Development to learn about its industry-leading Child Health Innovation Leadership Department.
The company's mission is to care for the world—one person at a time. Just ask Chief Medical Officer Joanne Waldstreicher, M.D., who's been leading the charge to improve the process by which very sick patients may apply for access to investigational medications.
Johnson & Johnson is committed to ethical decision-making and transparency to guide every decision we make. Read more for our scientific policies on sensitive topics.
These guidelines are to ensure that human pluripotent stem cell research conducted by Johnson & Johnson conforms to current international standards of scientific and ethical oversight, and that all scientists and employees of the Johnson & Johnson Family of Companies adhere to these ethical principles when conducting human pluripotent stem cell research.
Our Ethical Code for the Conduct of Research and Development is intended to complement our Credo by providing more specific standards of conduct and behavior for physicians, clinical research scientists and others who are responsible for medical aspects of research and development.
We believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our pharmaceutical products and providers who prescribe them.
We follow five important principles when providing pre-approval access to investigational medicines to patients with serious diseases to access medicines not yet approved by regulatory health authorities.
Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.
The heart condition affects up to six million Americans, and raises the risk of stroke five-fold. One patient describes what it was like to learn she had atrial fibrillation—and the unexpected positive impact it has had on her life.
Njira Lugogo, M.D., is a pulmonologist at the University of Michigan who is leading a clinical study of an investigational COVID-19 vaccine candidate. She helps answer common questions people may have about the process, from what people over 60 need to know to how participants are being kept safe during the pandemic.
June 11, 2020These guidelines are to ensure that human pluripotent stem cell research conducted by Johnson & Johnson conforms to current international standards of scientific and ethical oversight, and that all scientists and employees of the Johnson & Johnson Family of Companies adhere to these ethical principles when conducting human pluripotent stem cell research.
June 11, 2020Our Ethical Code for the Conduct of Research and Development is intended to complement our Credo by providing more specific standards of conduct and behavior for physicians, clinical research scientists and others who are responsible for medical aspects of research and development.
June 11, 2020We believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our pharmaceutical products and providers who prescribe them.
June 11, 2020We follow five important principles when providing pre-approval access to investigational medicines to patients with serious diseases to access medicines not yet approved by regulatory health authorities.
